#Class Action #Securities Fraud #Lantheus Holdings

Lantheus Holdings Investors Alert

Robbins Geller Rudman & Dowd LLP has announced a call to action for investors of Lantheus Holdings, Inc. (NASDAQ: LNTH) who acquired securities between February 26 and August 5, 2025. If you experienced significant financial losses during this time, you may have the opportunity to become the lead plaintiff in a class action lawsuit against the company.

Details of the Class Action

The lawsuit, titled Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.), charges Lantheus and several of its top executives with violations of the Securities Exchange Act of 1934. Investors interested in pursuing this legal action must file their applications to be appointed lead plaintiff by November 10, 2025.

Allegations Against Lantheus

According to the complaint, Lantheus is known for developing and marketing diagnostic and therapeutic products that aid in the diagnosis and treatment of diseases such as cancer and heart conditions. The company's key product, Pylarify, is a PET imaging agent used primarily for diagnosing prostate cancer. However, the lawsuit alleges that the company misrepresented its revenue growth and failed to accurately disclose the risks associated with market competition and pricing dynamics affecting its products.

In the complaint, it is stated that Lantheus projected optimistic sales growth for Pylarify while downplaying potential negative factors such as competition and broader economic fluctuations. It further alleges that the reality of product performance fell short of forecasts, leading to significant financial losses for investors.

Significant Stock Price Declines

The lawsuit outlines critical dates when damaging information became public regarding the performance of Pylarify. On May 7, 2025, Lantheus reported its first-quarter results, revealing a year-over-year decrease in sales due to a